Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.
Sensyne Health, a UK-based healthcare technology developer partially based on research at University of Oxford, raised £60m ($76m) in its initial public offering on Tuesday and will begin trading on Aim tomorrow.
The company issued approximately 34.3 million shares, priced at £1.75 each. It expects to have a market capitalisation of £225m when it commences trading.
Sensyne Health is developing clinically validated digital health products, such as prescribed digital therapeutics and hospital systems for clinical care, that rely on artificial intelligence. It also plans on using the anonymised data generated from these services to drive drug discovery.
Its products include hospital patient monitoring system Send, gestational diabetes management app GDm-Health, chronic obstructive pulmonary disease monitoring platform Edge and CleanSpace, which enables users to monitor their personal exposure to air pollution.
Sensyne emerged in July 2017 as Drayson Health, when its parent company Drayson Technologies signed a five-year strategic research agreement…
